Roche will present new cancer research, including two late-breaking abstracts, at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid from 23 to 27 October, highlighting advances in lung cancer, breast cancer and other hard-to-treat tumours.

The presentations will feature Phase III results for divarasib, an investigational KRAS G12C inhibitor for lung cancer; new findings on giredestrant, an oral hormone therapy candidate for breast cancer; and data on Tam-Peli, a next-generation antibody-drug conjugate (ADC) being investigated across multiple solid tumours.

 

The data underscore Roche’s push to advance targeted therapies and treatment combinations aimed at improving outcomes for patients with significant unmet medical needs.

 

“Our presentations at ESMO 2026 highlight the depth and impact of Roche’s oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers,” said Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development. 

 

“From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer."

 

A key highlight will be Phase III results from the Krascendo 1 trial, which Roche says demonstrate divarasib’s efficacy and potential to advance treatment for patients with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).

 

Krascendo 1 is the only global head-to-head trial evaluating a next-generation KRAS G12C inhibitor against approved first-generation inhibitors. The results will be presented as a late-breaking abstract during a Presidential Symposium.

 

The findings could help define the role of next-generation targeted therapy in a lung cancer subtype driven by the KRAS G12C mutation.

 

Roche will also present new data on giredestrant, an investigational oral, potent next-generation selective oestrogen receptor degrader (SERD) and full antagonist, in oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

 

More than 90% of cases of this breast cancer subtype are diagnosed at an early stage, making treatment advances across the disease spectrum a key focus.

 

The presentations will include patient-reported outcomes from the Phase III lidERA Breast Cancer trial, assessing whether giredestrant’s improved efficacy compared with endocrine therapy can be achieved without compromising tolerability or health-related quality of life.

 

Additional findings will cover exploratory biomarker analyses from the evERA Breast Cancer trial, which is evaluating giredestrant in combination with everolimus in patients with advanced ER-positive, HER2-negative breast cancer following treatment with a cyclin-dependent kinase 4/6 inhibitor.

 

Roche will also present updated interim results for giredestrant plus inavolisib from the MORPHEUS Breast Cancer trial, which is evaluating treatment combinations for locally advanced or metastatic ER-positive, HER2-negative breast cancer.

 

Together, the data will provide further insight into giredestrant’s potential across early-stage and advanced disease.

 

Roche will present new findings for Tam-Peli (tambotatug pelitecan), an investigational next-generation B7-H3-targeted ADC designed to deliver potent anti-tumour activity while limiting off-target toxicity.

 

The data include late-breaking interim Phase III results in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma, analyses of interstitial lung disease in patients with advanced solid tumours from Phase I/II studies, and Phase I efficacy and safety findings in patients with locally advanced or metastatic NSCLC.

 

The latest findings build on Phase III results from the TAISHAN-302 trial in second-line small cell lung cancer, presented at the World Conference on Lung Cancer in September. The study met all three specified endpoints at its first interim analysis: overall survival, progression-free survival and objective response rate.

 

Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau, and plans to rapidly initiate global trials across multiple tumour types.

 

Roche’s ESMO 2026 programme brings together investigational targeted therapies, oral endocrine treatments and ADCs, reflecting the company’s strategy to develop new options across cancers where treatment needs remain high.